PP.34.05

Abstract

Objective: Stroke is a common long-term condition with an increasing incidence as the population ages. Stroke symptoms often include cognitive impairment. Dyslipidemia is a well-known risk factor for stroke. The aim of the study was to investigate the cognitive impairment, lipid profile characteristics and patterns of statin therapy in patients with non-hemorrhagic stroke. Design and method: In 100 patients with acute ischemic stroke (42% male, 69.2 ± 8.9 (M ± SD) years, current smoking 30%, abdominal obesity 74%, arterial hypertension 97%, myocardial infarction 14%, previous non-hemorrhagic stroke 35%, diabetes mellitus 19%, brachiocephalic atherosclerosis 78%, atrial fibrillation 23%, chronic heart failure NYHA II/III 32/4%, chronic kidney disease 12%, estimated glomerular filtration rate 67.1 ± 17.1 ml/min/1.73 m2, alcohol abuse 12%, anemia 13%, previous statin therapy 9% the cognitive impairment, lipid profile characteristics and frequency of statin therapy were assessed. Cognitive functions were evaluated by using the Montreal Cognitive Assessment (MoCA) scale. Results: 96 (96%) patients had cognitive disfunction: 20.1 ± 4.3 scores by MoCA scale. 86 (86%) patients had dyslipidemia. The mean levels of lipids were 5.5 ± 1.3 mmol/l for total cholesterol (TC), 1.1 ± 0.3 mmol/l for HDL-C, 3.6 ± 0.9 mmol/l for LDL-C and 2.1 ± 0.6 mmol/l for triglycerides (TG). 17 (17%) patients were treated by statins during hospitalization. All of them took a low-dose statin. Conclusions: 96% of patients with non-hemorrhagic stroke have cognitive impairment according to MoCA scale, 86% of patients have dyslipidemia, only 9% and 17% of patients receive low-dose statin therapy ambulatory and at hospital respectively. There is a substantial gap between the guidelines and real practice of statin therapy.